Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clifutinib vs Salvage Chemotherapy in R/R FLT3-mutated AML
NCT05586074Phase 3Recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Mar 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clifutinib in acute myeloid leukemia (AML), sponsored by Sunshine Lake Pharma. Started Mar 2023; status: recruiting.
02
Drugs
clifutinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05586074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586074.